JAK Inhibitors Show Promise for Alopecia, Eczema, Vitiligo

That will likely happen soon, Dr King told Medscape Medical News. He said he expects a JAK inhibitor to be approved for the treatment of moderate to severe eczema in 2 years and for the treatment of moderate to severe alopecia areata in 2 to 3 years.

“We’ll see what we can do in vitiligo in the next year to make the case for large clinical trials,” he added.

Tofacitinib and ruxolitinib have had parallel successes, but tofacitinib was the focus of Dr King’s presentation here at the American Academy of Dermatology Annual Meeting. This was in part, he explained, because ruxolitinib costs “more than $100,000 per year and tofacitinib is more in the range of biologics.”

Evidence supporting the use of tofacitinib for alopecia areata is mounting, he pointed out.

Next Page

Be the first to comment

Leave a Reply

Your email address will not be published.